Rallybio Corporation — Q1 2023 Form 10-Q Summary
Business context and reporting period
Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases. Its lead clinical programs are RLYB212 for prevention of fetal and neonatal alloimmune thrombocytopenia and RLYB116, a C5 complement inhibitor. Additional programs include RLYB114, RLYB331 and discovery collaborations with Exscientia and AbCellera. The filing covers the three months ended March 31, 2023 and was filed May 9, 2023.
The company has no approved products and has never generated revenue from product sales. It had 43 full-time employees as of March 31, 2023.
Financial highlights
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | None | None | No product revenue |
| Research and development expense | $11.2 million | $7.6 million | +$3.6 million |
| General and administrative expense | $7.2 million | $6.7 million | +$0.5 million |
| Total operating expenses | $18.4 million | $14.3 million | +$4.1 million |
| Operating loss | $18.4 million | $14.3 million | Loss increased by $4.1 million |
| Interest and other income, net | $1.6 million | $0.2 million | +$1.4 million |
| Loss on joint venture investment | $0.6 million | $0.4 million | +$0.2 million |
| Net loss | $17.3 million | $14.5 million | Loss increased by $2.8 million |
| Basic and diluted loss per share | $0.43 loss | $0.48 loss | Improved per share loss due primarily to higher share count |
| Net cash used in operating activities | $18.8 million | $13.7 million | Use increased by $5.0 million |
Profitability and margins are not meaningful because the company has no revenue and remains loss-making. Share-based compensation expense was $3.0 million, compared with $2.1 million in the prior-year quarter.
Balance sheet, liquidity and capital resources
- Cash and cash equivalents were $39.5 million at March 31, 2023, down from $57.0 million at December 31, 2022.
- Marketable securities were $110.9 million, resulting in total cash, cash equivalents and marketable securities of approximately $150.4 million.
- Total assets were $162.3 million and total liabilities were $7.1 million.
- Stockholders’ equity was $155.2 million, compared with $169.3 million at year-end 2022.
- The filing reports no credit facility, debt financing or other material financing commitment. Operating lease liabilities totaled approximately $0.5 million.
- Management expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital requirements into the first quarter of 2025, while also stating that the balance will not fund development through regulatory approval and commercialization.
- The company has an effective shelf registration for up to $300 million and an at-the-market facility of up to $100 million; no shares had been sold under the ATM facility as of March 31, 2023.
Cash flow and material period-over-period changes
- Operating cash use increased to $18.8 million from $13.7 million, primarily because of higher research and development spending and personnel costs.
- Investing activities provided $1.5 million, compared with $80.2 million of investing cash use in Q1 2022. The change primarily reflected maturities of marketable securities rather than the prior-year purchases.
- Financing cash use was $0.1 million, consisting of offering costs.
- R&D spending increased principally because RLYB212 clinical development and manufacturing costs rose by $3.1 million and RLYB116 costs increased by $0.6 million. RLYB114 costs declined by $1.1 million.
- RLYB211 development was discontinued in March 2023 in favor of RLYB212, which management believes offers advantages in subcutaneous dosing and manufacturing and supply efficiency.
Clinical progress, outlook and unusual items
- RLYB212 achieved reported Phase 1b proof-of-concept: one week after a single subcutaneous dose, platelet elimination half-life was reduced by more than 90% in both dose groups versus placebo. Management expects Phase 1 multiple-dose cohort results in Q4 2023.
- The company expects initial multiple-dose data from the RLYB116 Phase 1 study in Q4 2023 and plans to discuss potential indications alongside those data.
- The FNAIT natural history study may screen up to 30,000 expectant mothers and is intended to support a future Phase 2/3 registration strategy and regulatory discussions.
- RLYB114 remains in preclinical development, with a goal of partnering the program with an ophthalmology specialist. Rallybio entered a research collaboration with EyePoint in February 2023.
- RLYB331 remains in IND-enabling development. The Exscientia collaboration is pursuing a development candidate for hypophosphatasia, with preclinical efficacy data expected in the second half of 2023.
- The company expects significant additional operating losses and will require substantial additional capital to complete development and potential commercialization. Future financing could dilute stockholders, impose debt covenants or require licensing rights to be surrendered.
- Key execution risks include clinical-trial enrollment and results, regulatory approval, companion-diagnostic requirements, third-party manufacturing and CRO dependence, intellectual property protection, competition, reimbursement and market acceptance.
- The filing reports no material litigation, no off-balance-sheet arrangements and no material changes in contractual obligations. Management concluded that disclosure controls were effective as of March 31, 2023.
Most important facts for investors to verify
- Whether RLYB212’s early proof-of-concept results translate into durable clinical and regulatory support in larger, registrational studies.
- Whether the Q4 2023 RLYB212 and RLYB116 data releases occur on schedule and support continued investment in both programs.
- Whether the company’s projected cash runway into Q1 2025 remains valid as clinical, manufacturing and natural-history-study costs develop.
- The timing, size and terms of any future equity, debt, collaboration or licensing financing, including potential dilution from the ATM facility and outstanding pre-funded warrants for up to 3.3 million shares.
- Whether regulatory authorities require a companion diagnostic or additional clinical evidence for RLYB212.
- Clinical-trial enrollment, safety, efficacy and manufacturing risks for RLYB212 and RLYB116, particularly given their early development stage.
- The economic value and obligations associated with licenses, collaborations and the Exscientia joint venture, including potential milestone and royalty payments.